Turn Therapeutics (TTRX) Notes Payables (2025 - 2026)

Turn Therapeutics (TTRX) posted quarterly Notes Payables of $2.8 million for Q1 2026, down 8.62% quarter-over-quarter from $3.0 million in Q4 2025.

Turn Therapeutics (TTRX) Notes Payables (2025 - 2026) Analysis & Trends

Turn Therapeutics' Notes Payables history runs 2 years deep, the most recent figure standing at $2.8 million for Q1 2026.

In Q1 2026, Notes Payables changed N/A year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $2.8 million (changed N/A YoY), while the FY2025 annual figure was $3.0 million, changed N/A from the prior year.
Notes Payables for Q1 2026 stood at $2.8 million, down from $3.0 million in the prior quarter.
The five-year high for Notes Payables was $3.0 million in Q4 2025, with the low at $2.8 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Turn Therapeutics	285.07 Mn	285.07 Mn	-

Download Data